(phase 1/2 study of combined therapy with meclofenamate and temozolozomide in the first recurrence of MGMT-methylated glioblastoma)

Based on promising laboratory data, the MecMeth trial is the first clinical trial to introduce combined temozolomide/meclofenamate therapy in patients with relapsed MGMT promoter-methylated glioblastoma. Meclofenamate disrupts tumor cell networks that mediate therapy resistance, thereby making tumor cells more susceptible to chemotherapy. Phase 1 will determine the optimal dose of meclofenamate in combination with temozolomide, which will then be investigated in a randomized Phase 2 trial for initial indications of improved efficacy. Phase 1 will enroll a maximum of 12 patients; Phase 2 will consist of two parallel groups of 30 patients each.